RELIEF THERAPEUTICS Holding AG (“Relief” or “Company”) today announces the agenda items for the Annual General Meeting of Shareholders (“AGM”) of May 30, 2017.
The Board is proposing a number of resolutions related to the optimization of the Company’s cost control measures that are being implemented to ensure business continuity, in particular the closure of the Zurich office and transfer of the Company’s Headquarters and domicile to Geneva. In connection therewith it is also proposed to generally translate the Articles of Association into French and to materially amend Article 1 (Company, Location, Duration, Purpose), Article 3a (Authorized share capital) and Article 3b (Conditional share capital) as well as to delete Article 3d (Conditional share capital II).
In connection with and in view of the Company’s efforts to reduce its costs and aggressively pursue its plan to refinance the company to ensure the development of its most promising Medicinal Product Candidates, Relief proposes to close its office in Zurich and move its headquarters and domicile to Geneva. Relief also proposes to re-elect as Members of the Board of Directors Messrs. Raghuram Selvaraju, Michel Dreano and Peter de Svastich. The Board also proposes to elect as independent new Board Member Mr. David A. Lowe, who is also serving as President and CEO of Neuroassets, from Switzerland. It is furthermore proposed to re-elect Mr. Raghuram Selvaraju as Chairman of the Board.
The invitation and the full wording of the proposed Articles of Association in French have today been published in the Swiss Official Gazette of Commerce. The formal invitations together with the registration form/proxy have been sent to the Shareholders registered in the share register with voting rights. Further information will also be available on the Relief website (www.relieftherapeutics.com).
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (Phase III-ready) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (Phase II-ready). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, and has been the subject of multiple clinical trials. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.
Tel: +41 44 723 59 59
This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding AG is providing this communication as of this date and does not undertake to update any forward looking statements contained herein as a result of new information, future events or otherwise.